Orphan Therapeutics, LLC is a privately held drug development company. It was founded in mid-2003 with the purpose to develop and seek FDA approval for its first product, LUCASSIN® (terlipressin), for the treatment of Hepatorenal Syndrome (HRS) type 1 in the US.